清髓性与减低强度预处理异基因造血细胞移植治疗既往实体瘤继发的治疗相关急性髓系白血病的结局比较:欧洲血液与骨髓移植学会急性白血病工作组报告
该注册研究纳入2000-2016年535例既往实体瘤继发的治疗相关急性髓系白血病患者,首次接受清髓性(MAC)或减低强度(RIC)异基因造血细胞移植。RIC组复发发生率升高(HR 1.52,95%CI 1.02-2.26,P=0.04),无白血病生存(HR 1.52,95%CI 1.12-2.05,P=0.007)和总生存(HR 1.51,95%CI 1.09-2.09,P=0.012)均较差,非复发死亡与无移植物抗宿主病无复发生存无差异。
要点
- RIC组复发风险高于MAC组(HR 1.52,95%CI 1.02-2.26,P=0.04)。
- RIC组无白血病生存(HR 1.52)和总生存(HR 1.51)均低于MAC组。
- 非复发死亡与无移植物抗宿主病无复发生存在两组间无差异。
核心结论
- 接受清髓性预处理的患者因复发减少而无白血病生存和总生存更优,作者认为随着非复发死亡持续下降,通过仔细选择适合清髓性预处理的患者可能改善此类移植结局。
研究设计与样本
- 欧洲血液与骨髓移植学会急性白血病工作组开展的大型注册研究,纳入2000-2016年首次接受MAC或RIC异基因造血细胞移植的535例既往实体瘤继发的治疗相关急性髓系白血病患者,主要终点为总生存和无白血病生存。
主要发现
- RIC组较MAC组复发发生率升高(HR 1.52,95%CI 1.02-2.26,P=0.04)。
- RIC组较MAC组无白血病生存更差(HR 1.52,95%CI 1.12-2.05,P=0.007)。
- RIC组较MAC组总生存更差(HR 1.51,95%CI 1.09-2.09,P=0.012)。
- 非复发死亡与无移植物抗宿主病无复发生存在两组间无差异。
关键数值与推荐
- 复发:RIC组较MAC组升高(HR 1.52,95%CI 1.02-2.26,P=0.04)。
- 无白血病生存:RIC组较MAC组更差(HR 1.52,95%CI 1.12-2.05,P=0.007)。
- 总生存:RIC组较MAC组更差(HR 1.51,95%CI 1.09-2.09,P=0.012)。
- 非复发死亡与无移植物抗宿主病无复发生存:两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy-related acute myeloid leukemia (t-AML) arises as a late complication following antecedent solid tumors or hematologic diseases and their associated treatments. There are limited data regarding risk factors and outcomes following allogeneic hematopoietic cell transplantation (HCT) for t-AML following a prior solid tumor, and furthermore, the impact of myeloablative (MAC) vs reduced-intensity conditioning (RIC) on survival is unknown. The acute leukemia working party (ALWP) of the European society for blood and bone marrow transplantation (EBMT) performed a large registry study that included 535 patients with t-AML and prior solid tumor who underwent first MAC or RIC allogeneic HCT from 2000-2016. The primary endpoints of the study were OS and LFS. Patients receiving RIC regimens had an increase in relapse incidence (hazard ratio [HR], 1.52; 95% confidence interval [CI] 1.02-2.26; P = 0.04), lower LFS (HR, 1.52; 95% CI 1.12-2.05, P = 0.007), and OS (HR, 1.51; CI 1.09-2.09; P = 0.012). There were no differences in NRM and GRFS. Importantly, LFS and OS were superior in patients receiving ablative regimens due to a decrease in relapse. As NRM continues to decline in the current era, it is conceivable that outcomes of HCT for t-AML with prior solid tumor may be improved by careful patient selection for myeloablative regimens.
引用
- Lee CJ, Labopin M, Beelen D, et al. Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019. PMID: 30597620. doi:10.1002/ajh.25395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。